Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 49Breast 13Genitourinary 12Myeloid 10Thoracic 9Plasma cell 9Classical hematology 9Gynecologic 8Head & Neck 5Tumor-Agnostic 4Other neoplasm 3Dermatologic 3Sarcoma 2Other hematologic neoplasm 2CNS 2Other solid neoplasm 1Other 1Lymphoid 1

Conditions

Melanoma 3

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Aspirin × Dermatologic × Clear all
NCT03396952 2022-10-13

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

University of California, San Francisco

Phase 2 Completed
27 enrolled 13 charts
Dermatologic

Melanoma

NCT04062032 2022-02-18

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

University of Utah

Phase 2 Completed
41 enrolled
Dermatologic

Melanoma

NCT04066725 2022-02-18

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

University of Utah

Phase 2 Completed
95 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡